Due to the fatal side effects of causing LQTS, several drugs have been withdrawn from the market since 1990s and the FDA now requires to test the drug effect on hERG activity during preclinical safety evaluation22,24. The gene discussed is KCNH2; the disease is familial long QT syndrome.